Overview
Morph Labs develops a non-invasive brain-computer interface (BCI) to control advanced prosthetics. It reads motor intent signals directly from the brain using high-density EEG, bypassing muscle-based EMG control. These neural signals are translated into precise motion commands for compatible devices, with adaptive machine-learning models that personalize in real time to reduce effort and increase precision. Compared with traditional EMG-based systems, Morph Labs aims to offer more natural control, higher degrees of freedom (prototypes show up to 19 DOF versus typical 5–10), and improved user experience. The platform targets amputees, clinics and neurology centers, and developers who can access signal-processing models via an API. Long-term, the company plans to extend its BCI work to exoskeletons, remote manipulators, and other applications, pursuing a broader goal of enabling non-invasive telekinesis through brain signals.
Work here?Claim your company
Simplify's take
What believers are saying
- Morph labs updated its site in October 2026, signaling active development and messaging.
- The company claims 10,000-plus hours of yearly motor-intent data to strengthen models.
- Leadership remains intact in New York, with Reddy, Cadavid, and Mehra publicly active.
What critics are saying
- Morph Labs says its technology is not sold and not FDA approved as of October 2026.
- EEG motor-intent decoding still faces noise, instability, and poor real-world reliability.
- Without clinical validation and reimbursement, Morph misses commercialization and becomes a research project.
What makes Morph Labs unique
- Morph Labs uses non-invasive EEG, avoiding surgery and muscle-fatiguing EMG control.
- Its platform targets 19 degrees of freedom, above typical five-to-ten prosthetic hands.
- The company is building reusable signal-processing APIs for prosthetics, robots, and remote manipulators.
Help us improve and share your feedback! Did you find this helpful?